Related Experiment Video
Updated: May 28, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer
Hee Jun Cho1, Kyoung Eun Baek, In-Koo Nam
1Department of Microbiology/Research Institute of Life Science, College of Natural Sciences, Gyeongsang National University, Jinju 660-701, Republic of Korea.
Abstract:
Rho GDP dissociation inhibitor 2 (RhoGDI2) is a regulator of the Rho family GTPases. Recent work from our laboratory suggests that RhoGDI2 expression potentially enhances resistance to cisplatin as well as promotes tumor growth and malignant progression in gastric cancer. In this study, we demonstrate that phospholipase C-gamma (PLCγ) is required for RhoGDI2-mediated cisplatin resistance and cancer cell invasion in gastric cancer. The levels of phosphorylated PLCγ are markedly enhanced in RhoGDI2-overexpressing SNU-484 cells and, by contrast, repressed in RhoGDI2-depleted MKN-28 cells. Depletion of PLCγ expression or inhibition of its activity not only significantly increases cisplatin-induced apoptosis but also suppresses the invasive ability of RhoGDI2-overexpressing SNU-484 cells. Taken together, our results suggest that PLCγ plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells.
Insights
Rho GDP dissociation inhibitor 2 (RhoGDI2) promotes gastric cancer progression and cisplatin resistance. Phospholipase C-gamma (PLCγ) is essential for these RhoGDI2 effects, making it a potential therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Rho GDP dissociation inhibitor 2 (RhoGDI2) regulates Rho GTPases and is implicated in gastric cancer progression.
- Previous studies suggest RhoGDI2 enhances tumor growth and cisplatin resistance in gastric cancer.
Purpose of the Study:
- To investigate the role of phospholipase C-gamma (PLCγ) in RhoGDI2-mediated cisplatin resistance and cancer cell invasion.
- To elucidate the molecular mechanisms linking RhoGDI2 and PLCγ in gastric cancer.
Main Methods:
- Analysis of RhoGDI2 and PLCγ expression levels in gastric cancer cell lines (SNU-484 and MKN-28).
- Manipulation of RhoGDI2 and PLCγ expression/activity using overexpression and depletion techniques.
- Assessment of cisplatin-induced apoptosis and cell invasion assays.
Main Results:
- RhoGDI2 overexpression correlated with increased phosphorylated PLCγ levels, while RhoGDI2 depletion reduced them.
- Inhibition of PLCγ activity or expression significantly enhanced cisplatin-induced apoptosis.
- Suppression of PLCγ also reduced the invasive capacity of RhoGDI2-overexpressing gastric cancer cells.
Conclusions:
- Phospholipase C-gamma (PLCγ) is a critical mediator of RhoGDI2's pro-survival and pro-invasion effects in gastric cancer.
- Targeting PLCγ may represent a viable strategy to overcome RhoGDI2-driven cisplatin resistance and metastasis in gastric cancer.
